Drug Utilization Review (DUR) Meeting Minutes
June 6, 2011

Members Present: Norman Byers, Jeffrey Hostetter, John Savageau, David Clinkenbeard, Russ Sobotta, Cheryl Huber, Kim Krohn, Greg Pfister, Patricia Churchill, Steve Irsfeld
Members Absent: James Carlson, Carrie Sorenson, Leann Ness, Todd Twogood, Carlotta McCleary
Medicaid Pharmacy Department: Brendan Joyce, Gary Betting
HID Staff Present: Candace Rieth

Chair, G. Pfister called the meeting to order at 1:06 pm. Chair, G. Pfister asked for a motion to approve the minutes from the March meeting. N. Byers moved that the minutes be approved and P. Churchill seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update
B. Joyce informed the board members that there is no budget update at this time. .

Nuedexta Second Review
A motion and second were made at the March meeting to place Nuedexta on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Nexiclon Second Review
A motion and second were made at the March meeting to place Nexiclon on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with one audible dissent.

Topical Ketoconazole Products Second Review
A motion and second were made at the December meeting to place topical ketoconazole products on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Sedative/Hypnotics, Qualaquin, ACE-I/ARB/Renin Inhibitors, Synagis, GH/IGF-1, and Triptan forms and criteria were reviewed. The board recommended that the triptan form include two steps for new starts. The first step would require failure of sumatriptan. The second step would require failure of naratriptan. There was no public comment. The form will be modified to include new recommendations.

Desoxyn Review
B. Joyce reviewed Desoxyn information with the Board. There was no public comment. After discussion, the board recommended that claims be verified for diagnosis of obesity or ADHD.

Colcrys Review
B. Joyce reviewed Colcrys information with the Board. There was no public comment. After discussion, the board tabled the topic for later review.

Asacol HD Review
B. Joyce reviewed Asacol HD information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Asacol HD on prior authorization. D. Clinkenbeard seconded the motion. This topic will be brought up at the next meeting for finalization.

Ophthalmic Antihistamine Review
B. Joyce reviewed ophthalmic antihistamine information with the Board. There was no public comment. After discussion, J. Hostetter made a motion to place ophthalmic antihistamines on prior authorization and include coverage of over the counter products. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

Horizant Review
B. Joyce reviewed Horizant with the Board. B. Felt, representing GSK, spoke regarding Horizant. After discussion, J. Hostetter made a motion to place Horizant on prior authorization. P. Churchill seconded the motion. This topic will be brought up at the next meeting for finalization.

Daliresp Review
B. Joyce reviewed Daliresp with the Board. C. McSpadden, representing Forest, spoke regarding Daliresp. After discussion, P. Churchill made a motion to place Daliresp on prior authorization. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Narcotics with high dose APAP Review
B. Joyce reviewed utilization of narcotics containing high doses of APAP. The FDA is requesting that drug manufacturers limit the amount of acetaminophen in prescription drug products to 325mg per tablet, capsule or other dosage unit. It is expected that the higher-dose formulations will be phased out by 2014. The department prefers to address this change proactively and therefore suggests that hydrocodone (5/325-10/325) and oxycodone (5/325-10/325) products are covered with all other strengths requiring prior authorization. There was no public comment. After discussion, J. Hostetter made a motion to place all strengths of narcotics in combination with acetaminophen except for hydrocodone/oxycodone (5/325-10/325) on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. P. Churchill moved to approve the new criteria and J. Savageau seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held September 12, 2011. P. Churchill made a motion to adjourn the meeting. J. Savageau seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 2:30 pm.